572880-47-8Relevant articles and documents
THERAPEUTIC AGENT FOR URINARY INCONTINENCE
-
Page/Page column 27, (2008/06/13)
PROBLEM TO BE SOLVED: To provide a new higher safe compound having higher effectiveness against urinary incontinence with smaller adverse effects. SOLUTION: A prophylactic and/or therapeutic agent for the urinary incontinence comprises a compound represented by formula (I) {wherein, A is a single bond or methylene; E and G are each a lower straight-chain alkylene which may be substituted with a lower alkyl; m is 0-5; R1s are each a halogen, a CF3, an OCF3, a CN, an NO2, a carboxy, an OH, an SH, a lower alkoxycarbonyl, a (substituted) carbamoyl, a lower alkanoyloxy, a (substituted) sulfamoyl group or a lower alkyl group or the like which may be substituted with an ORa (wherein, Ra is an H or a lower alkyl), a COORa, an SRa or an N(Ra)2; R2, R3 and R4 are each an H or a lower alkyl; n is 0-5; R5s are each a CN, an NO2, a COOH, an SO3H, a lower alkoxycarbonyl, a lower alkanoyl or the like; R6 and R7 are each an H or a lower alkyl which may be substituted with an ORa or a COOH; or an NR6R7 is a 5- to a 6-membered saturated heterocyclic ring}, an optically active substance or a pharmacologically acceptable salt thereof as an active ingredient. The drug exhibits excellent effects on treatment and/or prophylaxis of the urinary incontinence without causing adverse effects on the cardiovacular system such as blood pressure elevation.
